Indiana Biosciences Research Institute Names Lilly Executive Jay McGill Chief Operating Officer
January 03, 2018
McGill brings vast experience in collaboration, partnership, research operations and ventures to the IBRI.
Indianapolis, January 3, 2017 – The Indiana Biosciences Research Institute (IBRI) today announced that Jay McGill, Ph.D., has been named chief operating officer. McGill formerly spent 28 years at Eli Lilly and Company in a variety of positions. Most recently, McGill was the Senior Director, Lilly Research Laboratories Operations, responsible for science and technology partnerships, where he served as the interface between academic institutions and scientists within Lilly Research Labs. McGill also oversaw Lilly's portfolio of research based public-private partnerships and consortium participation.
McGill brings vast experience in collaboration, partnership, research operations and ventures to the IBRI.
“Dr. McGill’s expertise encompasses scientific excellence, an entrepreneurial mindset, and a collaborative background – all of which are in alignment with the Institute’s core values and are essential for moving our programs forward,” said Rainer Fischer, Ph.D., chief executive officer, IBRI. “With our scientific strategic plan in place, his knowledge implementing programs with Indiana’s innovation and academic research communities, as well as industry, will be invaluable.”
In 2013 and 2014, McGill was on assignment as a Lilly loaned executive at BioCrossroads, where he was translational scientific officer. His responsibilities included the support of several initiatives at the Indiana Clinical and Translational Institute (Indiana CTSI) at the Indiana University School of Medicine. McGill was instrumental in establishing the Indiana CTSI–Covance partnership for a Phase One clinic within Indiana University Health and played a critical role in creating the Strategic Pharma-Academic Research Consortium for Translational Medicine (SPARC).
“During my time at BioCrossroads, I did some early work on the IBRI and was very excited about the vision of the Institute,” said McGill. “Now a few years later, it is very rewarding to see the progress they’ve made, and I’m thrilled to help lead it through its next phase of world class scientific discovery and innovation.”
In addition to strengthening industry collaborations, Fischer and McGill are planning to pursue additional work with academic partners and other stakeholders in Indiana.
The IBRI currently has three scientific core competencies: Regenerative Medicine and Metabolic Biology, Single Cell Analytics and Applied Data Sciences with active projects and programs in each. And, recently announced a partnership with Ball State University, Indiana University, Purdue University and the University of Notre Dame to license available life sciences technologies at pre-defined terms.
About the Indiana Biosciences Research Institute
The Indiana Biosciences Research Institute (IBRI) is an independent, nonprofit discovery science and applied research institute focused on innovation targeting cardio-metabolic diseases, diabetes and poor nutrition. Inspired by the state and Indiana’s leading life sciences companies, research universities and philanthropic community, the IBRI is building a world-class organization of researchers, innovators, and entrepreneurs that will catalyze scientific discovery and its application, resulting in improved health outcomes for patients. Initial funding was provided by the State of Indiana, Lilly Endowment, Eli Lilly and Company, Dow AgroSciences, Roche Diagnostics, Indiana University Health and the Indiana University School of Medicine. IBRI is looking to expand partnerships with life sciences companies and philanthropic organizations to increase the potential for research, discovery, and collaboration. For more information about IBRI, please visit www.indianabiosciences.org